Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing therapies for rare diseases. The company uses its proprietary TransCon technology to create long-acting prodrugs. Despite its innovative approach, Ascendis faces challenges in capital efficiency, as indicated by its financial metrics.Ascendis Pharma's ROIC is -18.95%, which is significantly lower than its WACC of 5.88%. This negative ROIC suggests that the company is not generating sufficient returns to cover its cost of ...

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to ...

Outside the U.S., Ascendis said YORVIPATH is available commercially or through named patient programs in more than 30 countries , with full commercial reimbursement in four Europe Direct markets and two international markets . In Japan, partner Teijin launched YORVIPATH commercially in November 2025. Looking ahead, management said it expects full commercial launches in 10 additional new countries in 2026 .In the U.S., management said access continued to expand, with more than 5,300 patients prescribed YORVI ...

Ascendis Pharma (NasdaqGS:ASND) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsAlex Thompson - Managing DirectorChad Fugere - VP of Investor RelationsDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHeidi Jacobson - Equity Research AssociateJan Møller Mikkelsen - President and CEOJay Wu - EVP and President of US MarketLeland Gershell - Managing DirectorMaxwell Skor - VP in Biotech Equity ResearchScott Smith - CFOConference Call ParticipantsDaniel Brander - Equit ...

Ascendis Pharma (NasdaqGS:ASND) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsAlex Thompson - Managing DirectorChad Fugere - VP of Investor RelationsDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHeidi Jacobson - Equity Research AssociateJan Møller Mikkelsen - President and CEOJay Wu - EVP and President of US MarketLeland Gershell - Managing DirectorMaxwell Skor - VP in Biotech Equity ResearchScott Smith - CFOConference Call ParticipantsDaniel Brander - Equit ...

Ascendis Pharma (NasdaqGS:ASND) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Speaker2Thank you for standing by and welcome to the Ascendis Pharma's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business updat ...

Core Insights - Ascendis Pharma A/S is focused on developing treatments for unmet medical needs, with notable products including SKYTROFA for growth hormone deficiency and other treatments in its pipeline [1] Group 1: Stock Performance and Analyst Sentiment - The consensus price target for Ascendis Pharma's stock has increased from $270.50 a year ago to $307.33 in the last month, indicating growing optimism among analysts [2] - Bank of America Securities analyst Tazeen Ahmad has set a conservative price target of $161, reflecting some caution in the market [2] Group 2: Financial Performance - Ascendis Pharma reported Q3 revenues of €213.6 million, nearly four times higher than the previous year, driven by Yorvipath and SKYTROFA [3][5] - The company achieved operating profitability for the quarter, indicating strong financial performance [3] Group 3: Upcoming Events and Growth Prospects - The FDA PDUFA date for TransCon CNP on February 28th is critical, as approval could open a multi-billion-euro market for the company [4][5] - Ascendis Pharma has a solid cash position of €539 million, which supports continued investment in its pipeline and reduces near-term dilution risk [4]

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in a ...